72531-23-8

Basic information

• Product Name: 1-(4-Amino-3-chloro-phenyl)-ethanone
• Synonyms: 1-(4-AMINO-3-CHLORO-PHENYL)-ETHANONE;4'-Amino-2'-chloroacetophenone
• CAS NO: 72531-23-8
• Molecular Formula: C₈H₈ClNO
• Molecular Weight: 169.61
• Mol File: 72531-23-8.mol
• Article Data: 6

Chemical Properties

• Boiling Point: 304.1 °C at 760 mmHg
• Flash Point: 137.7 °C
• Appearance: /
• Density: 1.254 g/cm³
• PKA: 1.11±0.10(Predicted)
• CAS DataBase Reference: 1-(4-Amino-3-chloro-phenyl)-ethanone(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(4-Amino-3-chloro-phenyl)-ethanone(72531-23-8)
• EPA Substance Registry System: 1-(4-Amino-3-chloro-phenyl)-ethanone(72531-23-8)

Safety Data

• Hazardous Substances Data: 72531-23-8(Hazardous Substances Data)

Usage

Uses

1-(4-Amino-3-chlorophenyl)ethanone is an intermediate to many COX-II selective inhibitors.

Upstream product

• 67818-41-1 1-(2-chloro-4-nitrophenyl)ethanone 
• 99-60-5 2-chloro-4-nitrobenzoic acid 
• 7073-36-1 2-chloro-4-nitrobenzoyl chloride 
• 96042-30-7 4-(dicyanomethylene)-2-methyl-6-(p-dimethylaminostyryl)-4H-pyran 
• 588-07-8 3-Chloroacetanilide 
• 103273-72-9 acetic acid-(4-acetyl-3-chloro-anilide) 

Downstream Products

• 1134916-47-4 1-(2-chloro-4-diallylamino-phenyl)-ethanone 
• 345924-89-2 2-[(4-Acetyl-3-chloro-phenylamino)-methylene]-malonic acid diethyl ester 

Relevant articles and documents

Heterocyclic Compounds and Methods of Use

This disclosure provides compounds and methods of using those compounds to treat liver fibrosis, including liver fibrosis which is a precursor to, is concurrent with, is associated with, or is secondary to nonalcoholic steatohepatitis (NASH); elevated cholesterol levels, and insulin resistance.

HETEROCYCLIC COMPOUNDS AND METHODS OF USE

This disclosure provides compounds and methods of using those compounds to treat metabolic disorders and hyperproliferative disorders, including administration of the compounds in conjunction with hormone receptor antagonists.

GLUCOCORTICOID RECEPTOR ANTAGONISTS

The present invention relates to compounds of formula I wherein A, n, R1a to R1e and R2 to R5 are as defined in the description and claims, and pharmaceutically acceptable salts thereof. The compounds are glucoc